August 27, 2015
Chuikyo General Assembly Meeting on August 26 Gilead Sciences K.K.’s hepatitis C drug Harvoni (ledipasvir + sofosbuvir) cleared a key health ministry panel on August 26 for reimbursement listing later this month, but it stumbled on an unexpected hiccup at...read more